|
1）Yasui T, Iguchi M, Kohri K, et al. Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005. Urology. 2008; 71: 209-13
|
|
|
|
2）Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005; 26: 455-62
|
|
|
|
|
|
3）Takahashi S, Inokuchi T, Yamamoto T, et al. Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH. Horm Metab Res. 2007; 39: 511-4
|
|
|
|
|
|
4）Sakhaee K, Maalouf NM. Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol. 2008; 28: 174-80
|
|
|
|
|
|
5）Kohri K, Nomura S, Kitamura Y, et al. Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem. 1993; 268: 15180-4
|
|
|
|
|
|
6）Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009; 3: 311-22
|
|
|
|
|
|
7）Yasui T, Fujita K, Kohri K, et al. Osteopontin regulates adhesion of calcium oxalate crystals to renal epithelial cells. Int J Urol. 2002; 9: 100-8
|
|
|
|
|
8）Okada A, Nomura S, Kohri K, et al. Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney. J Bone Miner Res. 2008; 23: 1629-37
|
|
|
|
|
|
9）Hamamoto S, Okada A, Kohri K, et al. Effects of impaired functional domains of osteopontin on renal crystal formation: Analyses of OPN transgenic and OPN knockout mice. J Bone Miner Res. 2010; 25: 2712-23
|
|
|
|
|
|
10）Okada A, Yasui T, Kohri K, et al. Genome-wide analysis of genes related to kidney stone formation and elimination in the calcium oxalate nephrolithiasis model mouse: detection of stone-preventive factors and involvement of macrophage activity. J Bone Miner Res. 2009; 24: 908-24
|
|
|
|
|
|
11）Itoh Y, Okada A, Kohri K, et al. The role of long-term loading of cholesterol in renal crystal formation. Arch Ital Urol Androl. 2011; 83: 23-5
|
|
|
|
|
|
12）Yasui T, Okada A, Kohri K, et al. Aortic calcification in urolithiasis patients. Scand J Urol Nephrol. 2007; 41: 419-21
|
|
|
|
|
|
13）Okamoto M, Kohjimoto Y, Iba A, et al. Calcium oxalate crystal deposition in metabolic syndrome model rat kidneys. Int J Urol. 2010; 17: 996-1003
|
|
|
|
|
|
14）Jeong IG, Kang T, Bang JK, et al. Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kid Dis. 2011; 58: 383-8
|
|
|
|
|
|
15）Lange JN, Mufarrij PW, Wood KD, et al. The association of cardiovascular disease and metabolic syndrome with nephrolithiasis. Curr Opin Urol. 2012; 22: 154-9
|
|
|
|
|
|
16）Fujii Y, Okada A, Kohri K, et al. Effect of adiponectin on kidney stone formation in metabolic syndrome model mice via inhibition of inflammation and apoptosis. J Metabol Syndro. 2012; (in press)
|
|
|
|
|
|
17）Hamamoto S, Okada A, Kohri K, et al. Crucial role of the cryptic epitope SLAYGLR within osteopontin in renal crystal formation of mice. J Bone Miner Res.2011; 26: 2967-77
|
|
|
|
|
|
18）Ren Y, Sun C, Sun Y, et al. PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul Pharmacol. 2009; 51: 169-74
|
|
|
|
|
|
19）Taguchi K, Okada A, Kohri K, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces renal crystal deposition, oxidative stress, and inflammation in hyperoxaluric rats. J Urol. 2012; 188: 1002-11
|
|
|
|
|
|
20）Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med. 2001; 7: 941-6
|
|
|
|
|
|
21）Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem. 2002; 277: 37487-91
|
|
|
|
|
|
22）Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and apoE-deficient mice from atherosclerosis. J Biol Chem. 2003; 278: 2461-68
|
|
|
|
|